Latest news with #Edwards'
Yahoo
5 days ago
- Business
- Yahoo
Anthony Edwards vows to get better after Timberwolves' elimination: 'Nobody's going to work harder than me'
The Minnesota Timberwolves reached the Western Conference finals for the second straight season, only to once again fall short. The Oklahoma City Thunder dominated Minnesota from tip off, winning Game 5 by a score of 124-94 and cruising into the NBA Finals for the first time since 2012. After coming so close to the ultimate goal, Timberwolves star Anthony Edwards vowed to come back even better next season, saying, "Nobody's going to work harder than me this summer" following the loss. The thought of Edwards getting even better should strike fear into opposing defenders. Edwards, 23, averaged 27.6 points, 5.7 rebounds and 4.5 assists per game during the regular season. Edwards' 27.6 points per game ranked fifth among all NBA players and represented a career-high for the young superstar. While it could prove tough for Edwards to improve on those numbers, he shouldn't be counted out. Edwards has seen his scoring average increase every single season he's been in the league. After averaging 19.3 points as a rookie, Edwards has steadily pushed that number up. Those improvements have earned Edwards two All-Star appearances and one top-10 MVP finish. Despite that, Edwards and the Timberwolves continue to fall short in the playoffs. Edwards has reached the postseason in each of the past four seasons. While the Timberwolves have often outperformed their seeding, the team has yet to reach the Finals with Edwards. It isn't for lack of trying. Edwards has averaged 26.9 points, 6.6 rebounds and 5.5 assists over 42 career playoff games. Those figures are all higher than Edwards' regular-season averages over his career. He's stepped up his game when it's mattered the most. While those playoff losses might wear on some players, Edwards said he was excited about what's next. "I don't know why people would think it would hurt, it's exciting for me. I'm 23. I get to do it a whole bunch of times. ... We'll try again next year. But hurt is a terrible word to use. I'm good." Edwards has drawn comparisons to Chicago Bulls legend Michael Jordan due to the Timberwolves star's scoring ability and success at a young age. The two share another similarity. Both players experienced playoff failures early in their career. In Jordan's case, he continued to grow as the Bulls' roster improved. Once he broke through and reached the Finals, he seized the moment, winning every single time he got there. Putting those same expectations on Edwards would be foolish. You can't expect every NBA star to have the same trajectory as the GOAT. But the blueprint is there as long as Edwards has the drive and work ethic to keep pushing forward.
Yahoo
5 days ago
- Entertainment
- Yahoo
Anthony Edwards vows to get better after Timberwolves' elimination: 'Nobody's going to work harder than me'
The Minnesota Timberwolves reached the Western Conference finals for the second straight season, only to once again fall short. The Thunder dominated Minnesota from tip off, winning Game 5 by a score of 124-94 and cruising into the NBA Finals for the first time since 2012. After coming so close to the ultimate goal, Timberwolves star Anthony Edwards vowed to come back even better next season, saying, "Nobody's going to work harder than me this summer" following the loss. The thought of Edwards getting even better should strike fear into opposing defenders. Edwards, 23, averaged 27.6 points, 5.7 rebounds and 4.5 assists per game during the regular season. Edwards' 27.6 points per game ranked fifth among all NBA players and represented a career-high for the young superstar. While it could prove tough for Edwards to improve on those numbers, he shouldn't be counted out. Edwards has seen his scoring average increase every single season he's been in the league. After averaging 19.3 points as a rookie, Edwards has steadily pushed that number up. Those improvements have earned Edwards two All-Star appearances and one top-10 MVP finish. Despite that, Edwards and the Timberwolves continue to fall short in the playoffs. Edwards has reached the postseason in each of the past four seasons. While the Timberwolves have often over-performed their seeding, the team has yet to reach the Finals with Edwards. It isn't for lack of trying. Edwards has averaged 26.9 points, 6.6 rebounds and 5.5 assists over 42 career playoff games. Those figures are all higher than Edwards' regular-season averages over his career. He's stepped up his game when it's mattered the most. While those playoff losses might wear on some players, Edwards said he was excited about what's next. "I don't know why people would think it would hurt, it's exciting for me. I'm 23. I get to do it a whole bunch of times. ... We'll try again next year. But hurt is a terrible word to use. I'm good." Edwards has drawn comparisons to Chicago Bulls legend Michael Jordan due to the Timberwolves star's scoring ability and success at a young age. The two share another similarity. Both players experienced playoff failures early in their career. In Jordan's case, he continued to grow as the Bulls' roster improved. Once he broke through and reached the Finals, he seized the moment, winning every single time he got there. Putting those same expectations on Edwards would be foolish. You can't expect every NBA star to have the same trajectory as the GOAT. But the blueprint is there as long as Edwards has the drive and work ethic to keep pushing forward.
Yahoo
5 days ago
- Business
- Yahoo
Anthony Edwards vows to get better after Timberwolves' elimination: 'Nobody's going to work harder than me'
The Minnesota Timberwolves reached the Western Conference finals for the second straight season, only to once again fall short. The Thunder dominated Minnesota from tip off, winning Game 5 by a score of 124-94 and cruising into the NBA Finals for the first time since 2012. After coming so close to the ultimate goal, Timberwolves star Anthony Edwards vowed to come back even better next season, saying, "Nobody's going to work harder than me this summer" following the loss. Advertisement The thought of Edwards getting even better should strike fear into opposing defenders. Edwards, 23, averaged 27.6 points, 5.7 rebounds and 4.5 assists per game during the regular season. Edwards' 27.6 points per game ranked fifth among all NBA players and represented a career-high for the young superstar. While it could prove tough for Edwards to improve on those numbers, he shouldn't be counted out. Edwards has seen his scoring average increase every single season he's been in the league. After averaging 19.3 points as a rookie, Edwards has steadily pushed that number up. Those improvements have earned Edwards two All-Star appearances and one top-10 MVP finish. Despite that, Edwards and the Timberwolves continue to fall short in the playoffs. Edwards has reached the postseason in each of the past four seasons. While the Timberwolves have often over-performed their seeding, the team has yet to reach the Finals with Edwards. It isn't for lack of trying. Edwards has averaged 26.9 points, 6.6 rebounds and 5.5 assists over 42 career playoff games. Those figures are all higher than Edwards' regular-season averages over his career. He's stepped up his game when it's mattered the most. Advertisement While those playoff losses might wear on some players, Edwards said he was excited about what's next. "I don't know why people would think it would hurt, it's exciting for me. I'm 23. I get to do it a whole bunch of times ... We'll try again next year. But hurt is a terrible word to use. I'm good." Edwards has drawn comparisons to Chicago Bulls legend Michael Jordan due to the Timberwolves star's scoring ability and success at a young age. The two share another similarity. Both players experienced playoff failures early in their career. In Jordan's case, he continued to grow as the Bulls' roster improved. Once he broke through and reached the Finals, he seized the moment, winning every single time he got there. Putting those same expectations on Edwards would be foolish. You can't expect every NBA star to have the same trajectory as the GOAT. But the blueprint is there as long as Edwards has the drive and work ethic to keep pushing forward.
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
